All In Biotech

Free tool

FAERS Monitor: Neurontin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020235 or its brand name (Neurontin, Gabapentin). Reports on generic versions are filed under their own applications.

Reports

364,199

Serious

231,729

64% of reports

Hospitalization

107,727

Death reported

34,539

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective29,887
  • fatigue25,265
  • nausea23,025
  • pain21,365
  • off label use20,051
  • diarrhoea18,346
  • headache18,088
  • dizziness16,383
  • fall15,680
  • dyspnoea14,449
  • vomiting12,290
  • asthenia12,066
  • pain in extremity11,693
  • arthralgia11,623
  • death11,274

Reports by year received

View as table
YearReports
20043,727
20054,880
20064,578
20073,890
20083,697
20094,759
20107,706
20117,641
201210,961
201311,532
201414,043
201521,637
201625,871
201725,518
201830,289
201931,872
202027,335
202123,435
202222,063
202321,333
202420,663
202521,482
202615,281

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,689,960 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
fallSignal15,6802.82.817,643
pain in extremitySignal11,6932.32.38,786
painSignal21,3652.02.011,342
dizziness16,3831.91.97,241
fatigue25,2651.91.910,884
asthenia12,0661.91.84,910
nausea23,0251.71.76,702
headache18,0881.71.75,052
diarrhoea18,3461.71.64,826
arthralgia11,6231.61.62,821
vomiting12,2901.51.52,200
dyspnoea14,4491.51.52,303
off label use20,0511.31.31,673
drug ineffective29,8871.31.32,375
death11,2740.80.7944

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.